XORTX Extends Deadline for Vectus Renal Anti-Fibrotic Program Acquisition and Sets March Shareholder Meeting
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
XORTX Therapeutics Inc ( (TSE:XRTX) ) just unveiled an update.
On February 4, 2026, XORTX Therapeutics Inc. announced it had entered into an extension agreement with Vectus Biosystems to allow more time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program, including the novel small molecule VB4-P5, pushing the expected closing deadline to on or before March 31, 2026 to facilitate transfer of intellectual property and finalize closing conditions and regulatory approvals. The company also set March 24, 2026 as the date for its Annual and Special Meeting of Shareholders, established February 20, 2026 as the record date, and confirmed the grant of 20,000 stock options at an exercise price of CAD $0.69 to new director Krysta Davies Foss, signaling continued corporate governance activity and strategic expansion into kidney fibrosis, an area with no approved specific anti-fibrotic therapies and significant market potential.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.66 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Neutral.
The score is primarily constrained by weak financial fundamentals (no revenue, ongoing losses and cash burn, shrinking equity base) alongside a broadly weak technical trend (below key moving averages with negative MACD). Recent corporate actions are modest positives (capital raise and pipeline acquisition) but do not fully offset the reliance on external financing and dilution risk.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease. Its pipeline includes three clinically advanced programs: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney and other organ injury associated with respiratory virus infections, along with a preclinical program, XRx-225, targeting Type 2 diabetic nephropathy. The company’s strategy centers on targeting aberrant purine metabolism and xanthine oxidase to reduce uric acid production, addressing substantial unmet needs in kidney disease and related indications.
Average Trading Volume: 7,589
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.73M
Learn more about XRTX stock on TipRanks’ Stock Analysis page.
